Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
26.38 USD | +3.90% | +12.11% | +30.21% |
Financials (USD)
Sales 2024 * | 6.35M | Sales 2025 * | 7.38M | Capitalization | 1.35B |
---|---|---|---|---|---|
Net income 2024 * | -151M | Net income 2025 * | -164M | EV / Sales 2024 * | 137 x |
Net cash position 2024 * | 480M | Net cash position 2025 * | 319M | EV / Sales 2025 * | 140 x |
P/E ratio 2024 * |
-8.47
x | P/E ratio 2025 * |
-8.91
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.46% |
Latest transcript on 4D Molecular Therapeutics, Inc.
1 day | +3.90% | ||
1 week | +12.11% | ||
Current month | +10.24% | ||
1 month | -5.72% | ||
3 months | +50.83% | ||
6 months | +144.94% | ||
Current year | +30.21% |
Managers | Title | Age | Since |
---|---|---|---|
Theresa Janke
FOU | Founder | 49 | 13-09-11 |
David Kirn
FOU | Founder | 62 | 13-09-11 |
Uneek Mehra
DFI | Director of Finance/CFO | - | 23-09-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Milligan
CHM | Chairman | 63 | 20-07-31 |
Susannah Gray
BRD | Director/Board Member | 63 | 20-06-30 |
Charles Theuer
BRD | Director/Board Member | 60 | 15-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.74% | 16 M€ | -5.09% | ||
0.06% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-02 | 26.38 | +3.90% | 456,873 |
24-05-01 | 25.39 | +6.10% | 694,880 |
24-04-30 | 23.93 | -1.32% | 359,827 |
24-04-29 | 24.25 | +4.30% | 315,392 |
24-04-26 | 23.25 | -1.19% | 322,784 |
Delayed Quote Nasdaq, May 02, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+30.21% | 1.3B | |
+26.28% | 42.68B | |
-3.99% | 42.4B | |
+45.32% | 40.04B | |
-6.20% | 28.31B | |
+6.36% | 24.94B | |
-21.47% | 18.96B | |
+27.58% | 12.3B | |
-2.75% | 11.95B | |
-2.02% | 11.55B |
- Stock Market
- Equities
- FDMT Stock